SPARC Receives Rare Pediatric Disease Priority Review Voucher Linked to FDA Approval of Sezaby®

manufacturing-news
Image Courtesy: Pixabay

Sun Pharma Advanced Research Company Ltd(SPARC) has announced that the United StatesFood and Drug Administration (FDA) has granted a Rare Pediatric Disease Priority Review Voucher (PRV) associated with the approval of Sezaby®. The PRV is a transferable voucher awarded by the FDA to encourage development of new therapies for rare pediatric diseases and can be redeemed to obtain priority review for a future, separate drug application.

Anil Raghavan, CEO of SPARC, said the PRV marks an important milestone for the company and reflects its focus on addressing urgent unmet medical needs. He added that the voucher not only recognises the value of Sezaby® but also provides SPARC with strategic flexibility to accelerate pipeline development and bring new therapies to patients sooner.

Sezaby® is a benzyl alcohol-free and propylene glycol-free formulation of phenobarbital sodium powder for injection. The FDA has approved the product for the treatment of neonatal seizures. SPARC is a pharmaceutical company focused on advancing standards of care through innovation in therapeutics and drug delivery. The company works toward improving efficiency, reducing costs and supporting the wider availability and affordability of treatments for patients globally.

Sun Pharma Advanced Research Company Limited (SPARC) is an Indian clinical-stage biopharmaceutical company focused on discovering and developing innovative therapeutics to improve patient care globally. It was formed in 2007 after a strategic demerger from Sun Pharmaceutical Industries to create a standalone R&D-focused entity. SPARC primarily works in oncology, immunology, neurodegeneration, dermatology, and ophthalmology, advancing new chemical entities and biologics through clinical and preclinical stages. Its work includes novel drug molecules and delivery systems, often partnering with global pharmaceutical firms for commercialization. SPARC aims to address unmet medical needs by translating scientific research into effective treatments for complex diseases.